PRESS RELEASE published on 06/24/2024 at 22:05, 1 year 8 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 1 year 9 months ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
BRIEF published on 05/28/2024 at 13:05, 1 year 9 months ago CureVac annonce le dosage du premier participant à l'étude de phase 2 sur la grippe GSK Technologie ARNm Étude De Phase 2 CureVac Vaccin Contre La Grippe
PRESS RELEASE published on 05/28/2024 at 13:00, 1 year 9 months ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 1 year 9 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
BRIEF published on 05/23/2024 at 13:05, 1 year 9 months ago CureVac annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités Résultats Financiers Mise À Jour De L'entreprise T1 2024 CureVac Procédure Accélérée De La FDA
PRESS RELEASE published on 05/23/2024 at 13:00, 1 year 9 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 1 year 10 months ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:11, 1 year 10 months ago CureVac annonce ses résultats financiers pour 2023 et des mises à jour stratégiques sur ses activités Technologie ARNm CureVac Collaborations Pharmaceutiques Vaccins Contre L'oncologie Vaccins Prophylactiques
BRIEF published on 04/24/2024 at 13:08, 1 year 10 months ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 03/23/2026 at 11:30, 26 minutes ago Trans Canada Gold Provides Update on Non-Brokered Private Placement and Flow-through Private Placement for Drilling at the Harrison Lake District Scale Gold Property Acquisition
Published on 03/23/2026 at 08:00, 3 hours 56 minutes ago ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 9 hours 56 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/23/2026 at 11:44, 11 minutes ago Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
Published on 03/23/2026 at 11:30, 26 minutes ago EQS Group lance un module de gestion des risques pour faciliter la surveillance continue des risques liées aux données et à l’IA
Published on 03/23/2026 at 11:06, 49 minutes ago Aroundtown SA: Release of a capital market information
Published on 03/23/2026 at 11:05, 50 minutes ago ASUS Unveils Complete Portfolio Support for Intel® Core™ 200S Series
Published on 03/23/2026 at 11:05, 51 minutes ago BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology
Published on 03/23/2026 at 08:10, 3 hours 46 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 16 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 17 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
